<DOC>
	<DOCNO>NCT00707135</DOCNO>
	<brief_summary>The goal study determine rapamycin dose equivalent recommend phase II/III dose temsirolimus determine observe toxicity anti-tumor response rapamycin patient advance cancer .</brief_summary>
	<brief_title>Rapamycin Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . Patients hematologic malignancy ( lymphoma CLL ) eligible participate phase Ib portion trial . Patients must relapse refractory disease longer amenable standard available therapy . At least 4 week since prior chemotherapy radiation therapy Age &gt; 18 year ECOG performance status less equal 2 Life expectancy great 3 month . Normal organ marrow function define : No transfusion pack red blood cell 1 week start treatment . An absolute level hemoglobin constitute eligibility criterion patient transfuse clinically indicate . Leukocytes ≥ 3,000/μL WBC ≥ 1,500/μL patient hematologic malignancy ANC ≥ 1,500/μL ( ≥1,000/μL patient hematologic malignancy ) Absolute lymphocyte count ≥ 1000/µL CD4 count ≥ 500/μL Platelets ≥ 100,000/μL ( ≥50,000/μL patient hematologic malignancy ) Total bilirubin within normal institutional limit AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time institutional upper limit normal Serum triglyceride ≤ 500 mg/dl Creatinine within normal institutional limit OR Creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level institutional normal . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Ability understand willingness sign write informed consent document . Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study . Not recovered adverse event due agent administer 4 week earlier . May receive investigational agent . Uncontrolled brain metastasis malignancy . Patients brain metastasis malignant primary brain tumor must stable neurologic status follow local therapy ( surgery radiation ) least 8 week definitive therapy , must without neurologic dysfunction would confound evaluation neurologic adverse event . Patients receive enzyme inducing anticonvulsant . History allergic reaction attribute compound similar chemical biologic composition rapamycin . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , history interstitial lung disease ( include pneumonitis , bronchiolitis obliterans organize pneumonia , pulmonary fibrosis ) psychiatric illness/social situation would limit compliance study requirement . Patients severe immunodeficient state ( judge treat physician . Pregnant woman , breastfeed must stop HIVpositive patient exclude due possible pharmacokinetic interaction rapamycin . Concurrent use ketoconazole , cyclosporine , tacrolimus , rifampin rapamycin permissible . Concurrent use rapamycin diltiazem allow do caution avoid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>